During the last few years cochlear implantation (CI) has made remarkable progress, developing from a mere research tool to a viable clinical application. The Centre for CI in the Northern Ireland was established in 1992 and has since been a provider of this new technology for rehabilitation of profoundly deaf patients in the region. Although individual performance with a cochlear implant cannot be predicted accurately, the overall success of CI can no longer be denied. Seventy one patients, 37 adults and 34 children, have received implants over the first five years of the Northern Ireland cochlear implant programme, which is located at the Belfast City Hospital. The complication rates and the post-implantation outcome of this centre compare favourably with other major centres which undertake the procedure. This paper aims to highlight the patient selection criteria, surgery, post-Cl outcome, clinical and research developments within our centre, and future prospects of this recent modality of treatment.
INTRODUCTION
Experiments by Volta were the first recorded attempts at electrical stimulation of the auditory system. More recent efforts at electrical stimulation of the auditory nerve began in 1957 by Djourno 15, 000 CIs have been done world wide. A multichannel cochlear implant consists of two parts, a receiver stimulator implanted in the temporal bone consisting of a receiver coil with an electrode array inserted into the cochlea, and an external device. The three main components of the external device are the microphone, speech processor and a transmitter coil conveying signals from the processor across the skin to the electrode array (Fig 1) . The microphone picks up sounds and transfers them to the speech processor. These sound signals are analysed and converted to a form suitable for transmission by the processor. In most devices these transformed signals reach the electrodes by radio-frequency transmission from the transmitter coil resting on the head to the implanted receiver coil. Profound deafness in the majority of cases results from damage to the sensory cells in the 'Organ of Corti' in the inner ear, due to various causes. CI helps this group of patients since it bypasses the damaged part of the auditory pathway and stimulates the surviving spiral ganglion cells directly with electrical signals. Early CI systems were mostly single-channel; with the advent of home the day after surgery.
Results
The outcome of all the adults and children implanted during the first five year period was assessed. In adults the Bench Kowal Bamford (BKB) sentence tests were used to assess speech perception. Routinely assessments are carried out at 1, 9 and 24 month intervals post-operatively. Of the 37 adults implanted one patient was lost for follow up and another patient died due to unrelated causes before the 9 month assessment. Figure 2 shows the mean results of the remaining 35 adults implanted. This phase which lasts about a year in adults is much prolonged in children, and lasts at least 3 years. This is followed by the maintenance phase which lasts as long as the device is being used by the patient. Routinely, 6 monthly visits for adults and 3 to 6 monthly visits for children are arranged.
CONCLUSION
In the present era of 'evidence based medicine', for a health technology to be concluded as beneficial it must be supported by outcome data. The main report by the MRC Institute of hearing research on the evaluation ofthe national cochlear implant programme in the UK confirms with relevant data the benefits of CI for the rehabilitation ofdeafpatients. 16 All the 7 1 patients in this study developed environmental sound awareness and a variable degree of expressive language and speech discrimination. CI research is developing rapidly, presently an 'ear level' multi-channel processor is available similar in appearance to a behind-the ear-hearing aid. As further progress is made and we edge towards the millennium, it is hoped that a completely implantable device with improved speech processing technology will soon be available.
